Please assess the completion status of the following clinical trial:

Trial Title: F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of metastatic breast cancer~  * No cutaneous metastases on hands or feet~* Pegylated liposomal doxorubicin hydrochloride monotherapy is indicated according to the local investigator~  * Planned dose at least 10 mg/m\^2 per week~* No sign of palmar-plantar erythrodysesthesia (PPE) at study entry~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Able to apply topical medication (cream) or provide for another person to apply cream~* Not pregnant or breastfeeding~* Fertile patients must use effective contraception during trial participation and for 1 month after completion~* Negative pregnancy test~* Compliant and geographically proximal in order to allow proper evaluation and follow-up~* No dermatologic conditions (e.g., psoriasis) that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment~* No known allergy or hypersensitivity to F511 cream~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 30 days since prior and no concurrent treatment with other experimental drugs or anticancer therapy~* More than 30 days since prior and no concurrent treatment on another clinical trial~* No concurrent local use of other ointments or creams for hands or feet other than Excipial Repair®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).